| 79.21 5.54 (7.52%) | 07-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 96.36 |
1-year : | 112.54 |
| Resists | First : | 82.5 |
Second : | 96.36 |
| Pivot price | 75.3 |
|||
| Supports | First : | 74.42 |
Second : | 69.44 |
| MAs | MA(5) : | 75.25 |
MA(20) : | 76.08 |
| MA(100) : | 68.96 |
MA(250) : | 72.16 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.9  |
| %K %D | K(14,3) : | 45 |
D(3) : | 30.1 |
| RSI | RSI(14): 61.4 |
|||
| 52-week | High : | 99.5 | Low : | 40 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IRON ] has closed Bollinger Bands are 33.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 79.39 - 79.76 | 79.76 - 80.12 |
| Low: | 72.61 - 73.02 | 73.02 - 73.41 |
| Close: | 78.49 - 79.18 | 79.18 - 79.82 |
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Thu, 30 Jul 2026
Disc Medicine (NASDAQ:IRON) Releases Earnings Results, Beats Estimates By $0.17 EPS - MarketBeat
Thu, 30 Jul 2026
Disc Medicine Q2 Results: EPS beats estimates, losses narrow YoY - scanx.trade
Thu, 30 Jul 2026
Disc Medicine Inc (IRON) Eyes Key Pipeline Milestones Amid Mixed Market Signals - GuruFocus
Thu, 30 Jul 2026
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Thu, 30 Jul 2026
Disc Medicine reports Q2 net loss of $59.5M, cash of $717.7M; APOLLO topline due Q4 2026 - TradingView
Thu, 30 Jul 2026
Disc Medicine 2Q 2026: Net loss $(59.5M), EPS $(1.54) — 10-Q Summary - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 38 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 7.7 (%) |
| Held by Institutions | 112.9 (%) |
| Shares Short | 7,290 (K) |
| Shares Short P.Month | 6,010 (K) |
| EPS | -6.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.7 % |
| Return on Equity (ttm) | -35.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -201 (M) |
| Levered Free Cash Flow | -121 (M) |
| PE Ratio | -11.93 |
| PEG Ratio | 0 |
| Price to Book value | 4.39 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|